Skip to main content
. 2023 May 26;8:10. doi: 10.1038/s41525-023-00353-0

Table 2.

Exome sequencing results of P3EGS patients (based on pediatric inclusion criteria and prenatal phenotypes with ultrasound).

Definitive/probable positive n (%a) Inconclusive n (%a) Negative n (%a) Total n (%b)
Pediatric inclusion criteria (n = 529)
ID + MCA 71 (28.2) 31 (12.3) 150 (59.5) 252 (47.6)
MCA 29 (27.6) 16 (15.2) 60 (57.1) 105 (19.8)
ID only 8 (16.7) 6 (12.5) 34 (70.8) 48 (9.1)
Epilepsy + ID 9 (21.4) 8 (19.0) 25 (59.5) 42 (7.9)
NDD + ID 9 (29.0) 5 (16.1) 17 (54.8) 31 (5.9)
Metabolic disease, no ID 3 (25.0) 9 (75.0) 12 (2.3)
NDD, no ID 4 (40.0) 1 (10.0) 5 (50.0) 10 (1.9)
Metabolic disease + ID 4 (44.4) 3 (33.3) 2 (22.2) 9 (1.7)
Encephalopathy 2 (40.0) 3 (60.0) 5 (0.9)
Epilepsy no ID 1 (33.3) 2 (66.7) 3 (0.6)
Otherc 4 (33.3) 1 (8.3) 7 (58.3) 12 (2.3)
Pediatric patients total 141 (26.7) 74 (14.0) 314 (59.4) 529 (100.0)
Prenatal inclusion criteria by ultrasound findings at enrollment (n = 316)
Isolated anomaly 15 (12.0) 6 (4.8) 104 (83.2) 125 (39.6)
 Cardiovascular 3 (11.5) 3 (11.5) 20 (76.9) 26 (8.2)
 Central nervous system 4 (16.0) 0 (0) 21 (84.0) 25 (7.9)
 Neck 1 (5.3) 2 (10.5) 16 (84.2) 19 (6.0)
 Effusions 2 (12.5) 14 (87.5) 16 (5.1)
 Gastrointestinal tract 1 (6.7) 14 (93.3) 15 (4.7)
 Skeletal 2 (20.0) 8 (80.0) 10 (3.2)
 Genitourinary Tract 2 (28.6) 5 (71.4) 7 (2.2)
 Face 1 (50.0) 1 (50.0) 2 (0.6)
 Spine 2 (100.0) 2 (0.6)
 Abdominal wall 1 (100.0) 1 (0.3)
 Fetal growth alteration 1 (100.0) 1 (0.3)
 Hematologic/lymphatic/skin 1 (100.0) 1 (0.3)
 Ear
 Pulmonary
Multiple anomalies 45 (23.6) 14 (7.3) 132 (69.1) 191 (60.4)
Prenatal patients total 60 (19.0) 20 (6.3) 236 (74.7) 316 (100.0)

aRow %; bColumn %, ID Intellectual Disability, MCA Multiple Congenital Anomalies, NDD Neurodegenerative disorder/Cerebral palsy; Otherc Clinical findings associated with patients enrolled under ‘Other’ are provided with Table S12.